单药培美曲塞二线治疗晚期非小细胞肺癌临床观察  

Observation of pemetrexed single as the 2nd line treatment for advanced non-small cell lung cancer

作　　者：胡传朋[1] 

机构地区：[1]安徽医科大学附属六安医院肿瘤内科,安徽六安237005

出　　处：《安徽医药》2012年第1期94-95,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的评价单药培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法经病理学或细胞学确诊,一线化疗后出现复发或进展的晚期NSCLC患者27例。单药培美曲塞500 mg.m-2,第一天,21 d为1个周期。完成2个周期以上化疗评价疗效和不良反应。结果 27例中无CR病例,PR 1例,SD 16例,PD 10例,疾病控制率(PR+SD)62.9%(17/27),中位疾病进展时间(TTP)为2.9个月。不良反应主要为骨髓抑制和胃肠道反应。结论培美曲塞二线治疗晚期NSCLC安全有效,耐受性好。Objective To evaluate the efficacy and adverse of pemetrexed single as the 2nd line treatment for advanced non-small cell lung cancer（NSCLC）.Methods Confirmed with pathology or cytology,twenty-seven patients were advanced or progressive NSCLC patients after the first line chemotherapytreatment.All patients were given pemetrexed 500 mg·m-2 on the first day,21 days as one cycle;The chemotherapy efficacy and adverse reactions over 2 cycles were evaluated.Results There was no case with complete response.1 case had partial response,16 had stable disease and 10 progressive disease.The disease control rate was 62.9%（17/27）.The median time to progress（TTP） was 2.9 months.The common adverse effects were leucopenia and gastrointestinal response.Conclusion Pemetrexed is effective and feasible as the 2nd line treatment for advanced NSCLC.

关 键 词：培美曲塞 非小细胞肺癌 治疗 

分 类 号：R734.2[医药卫生—肿瘤]